ATHE ALTERITY THERAPEUTICS LTD

Nasdaq alteritytherapeutics.com


$ 3.68 $ -0.08 (-2.03 %)    

Tuesday, 11-Nov-2025 11:01:21 EST
QQQ $ 623.80 $ 0.00 (0 %)
DIA $ 480.13 $ 0.00 (0 %)
SPY $ 684.27 $ 0.00 (0 %)
TLT $ 89.68 $ 0.00 (0 %)
GLD $ 379.43 $ 0.00 (0 %)
$ 3.67
$ 3.79
$ 3.53 x 100
$ 3.89 x 100
-- - --
$ 1.00 - $ 7.00
2,962
na
320.83M
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alterity-therapeutics-presents-data-on-orthostatic-hypotension-from-its-ath434-201-phase-2-clinical-study-in-multiple-system-atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-presents-data-from-ath434-201-randomized-double-blind-phase-2-clinical-trial-in-msa-at-2025-international-congress-of-parkinsons-disease-and-mds

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall co...

 alterity-to-present-multiple-system-atrophy-drug-trial-results-at-major-parkinsons-conference-in-hawaii

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-phase-2-trial-shows-ath434-slowed-progression-of-rare-brain-disorder-msa

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-raises-20m-to-advance-fda-path-for-promising-neurodegenerative-drug

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-faces-asx-scrutiny-over-timing-of-market-sensitive-mri-study-announcement

Alterity Therapeutics Limited (‘ATH'): ASX Aware LetterASX refers to the following:A.ATH's announcement titled ‘Alterit...

 alterity-therapeutics-announces-topline-data-from-ath434-202-open-label-phase-2-clinical-trial-in-individuals-with-multiple-system-atrophy

– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms –– Neuroima...

 alterity-therapeutics-says-peer-reviewed-publication-in-annals-of-clinical-and-translational-neurology-highlights-use-of-msa-atrophy-index-developed-to-diagnose-and-track-disease-progression-in-multiple-system-atrophy

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION